Literature DB >> 17616027

Hand-foot syndrome with scleroderma-like change induced by the oral capecitabine: a case report.

Sehe-Dong Lee1, Hye-Jeong Kim, Seung-Jae Hwang, Yoon-Jung Kim, Seung-Hyun Nam, Bong-Seog Kim.   

Abstract

Hand-foot syndrome (HFS) is a well-known adverse event associated with capecitabine, a prodrug of 5-Fluorouracil (5-FU). HFS manifests as acral erythema, with swelling and dysesthesia of the palms and plantar aspects of the feet, which in the absence of dosage reduction or drug cessation, progresses to moist desquamation and ulceration, resulting in serious infections and loss of function. We report a case of HFS, with scleroderma-like changes, apparently induced by capecitabine. In our case, capecitabine, given in the recommended dosage was observed to lead to hyperpigmentation of the palms and soles, followed by a distinct keratoderma-like thickening unfamiliar to usual cases of HFS. This case may provide important clues for revising the definition of HFS, and allow the formation of effective preventive strategies for this side effect of chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17616027      PMCID: PMC2687614          DOI: 10.3904/kjim.2007.22.2.109

Source DB:  PubMed          Journal:  Korean J Intern Med        ISSN: 1226-3303            Impact factor:   2.884


  13 in total

Review 1.  Chemotherapy-induced acral erythema.

Authors:  B R Baack; W H Burgdorf
Journal:  J Am Acad Dermatol       Date:  1991-03       Impact factor: 11.527

2.  Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine.

Authors:  D R Budman; N J Meropol; B Reigner; P J Creaven; S M Lichtman; E Berghorn; J Behr; R J Gordon; B Osterwalder; T Griffin
Journal:  J Clin Oncol       Date:  1998-05       Impact factor: 44.544

3.  Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.

Authors:  P M Hoff; R Ansari; G Batist; J Cox; W Kocha; M Kuperminc; J Maroun; D Walde; C Weaver; E Harrison; H U Burger; B Osterwalder; A O Wong; R Wong
Journal:  J Clin Oncol       Date:  2001-04-15       Impact factor: 44.544

4.  Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.

Authors:  E Van Cutsem; C Twelves; J Cassidy; D Allman; E Bajetta; M Boyer; R Bugat; M Findlay; S Frings; M Jahn; J McKendrick; B Osterwalder; G Perez-Manga; R Rosso; P Rougier; W H Schmiegel; J F Seitz; P Thompson; J M Vieitez; C Weitzel; P Harper
Journal:  J Clin Oncol       Date:  2001-11-01       Impact factor: 44.544

5.  Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer.

Authors:  J L Blum; S E Jones; A U Buzdar; P M LoRusso; I Kuter; C Vogel; B Osterwalder; H U Burger; C S Brown; T Griffin
Journal:  J Clin Oncol       Date:  1999-02       Impact factor: 44.544

6.  Incidence and severity of hand-foot syndrome in colorectal cancer patients treated with capecitabine: a single-institution experience.

Authors:  Samer Abushullaih; Everardo D Saad; Mark Munsell; Paulo M Hoff
Journal:  Cancer Invest       Date:  2002       Impact factor: 2.176

7.  Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients.

Authors:  J Schüller; J Cassidy; E Dumont; B Roos; S Durston; L Banken; M Utoh; K Mori; E Weidekamm; B Reigner
Journal:  Cancer Chemother Pharmacol       Date:  2000       Impact factor: 3.333

8.  Hand-foot syndrome associated with liposome-encapsulated doxorubicin therapy.

Authors:  K B Gordon; A Tajuddin; J Guitart; T M Kuzel; L R Eramo; J VonRoenn
Journal:  Cancer       Date:  1995-04-15       Impact factor: 6.860

9.  First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin.

Authors:  J Cassidy; C Twelves; E Van Cutsem; P Hoff; E Bajetta; M Boyer; R Bugat; U Burger; A Garin; U Graeven; J McKendric; J Maroun; J Marshall; B Osterwalder; G Pérez-Manga; R Rosso; P Rougier; R L Schilsky
Journal:  Ann Oncol       Date:  2002-04       Impact factor: 32.976

Review 10.  Serious hand-and-foot syndrome in black patients treated with capecitabine: report of 3 cases and review of the literature.

Authors:  Parthas Narasimhan; Sudha Narasimhan; Ibrahim F Hitti; Mercea Rachita
Journal:  Cutis       Date:  2004-02
View more
  3 in total

1.  Palmar-plantar hyperpigmentation with capecitabine in adjuvant colon cancer.

Authors:  Michael M Vickers; Jacob C Easaw
Journal:  J Gastrointest Cancer       Date:  2009-05-14

2.  An unusual case of capecitabine hyperpigmentation: Is hyperpigmentation a part of hand-foot syndrome or a separate entity?

Authors:  Biju Vasudevan
Journal:  Indian J Pharmacol       Date:  2010-10       Impact factor: 1.200

3.  Scleroderma in a Patient on Capecitabine: Is this a Variant of Hand-Foot Syndrome?

Authors:  Muhammad W Saif; Archana Agarwal; James Hellinger; Dorothy J Park; Elizabeth Volkmann
Journal:  Cureus       Date:  2016-06-30
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.